The US government’s purchase of additional doses of Eli Lilly and Company’s monoclonal antibody drug for COVID-19 beyond the initial 300,000 dose order will depend on whether the health care system figures out how to administer it safely outside of the hospital inpatient setting, according to officials with Operation Warp Speed.
Lilly has signed a $375m contract with the government for 300,000 doses of bamlanivimab, to be delivered during November and December. The deal includes an option for the US to purchase an additional 650,000 vials through 30 June 2021 for $812.5m, subject to availability and medical need